

**Table S2. Principal characteristics of the studies included on EPHX1 Tyr113His polymorphism.**

First Author	Year	Country	Ethnicity	Cancer Type	Source of	Genotypes distribution			HWE	
						Control	(case/control)			
							TT	TC		CC
Conesa-Zamora	2013	Spain	Caucasian	lymphoma	PB	118/113	71/83	17/18	0.62	
Catsburg	2012	USA	Mixed	prostate cancer	PB	716/400	541/295	125/52	0.81	
Dura	2012	Holland	Caucasian	esophageal cancer	PB	178/295	136/228	30/58	0.16	
Nisa	2013	Japan	Asian	colorectal cancer	PB	228/239	342/396	115/143	0.35	
Jang	2012	Canada	Mixed	pancreatic cancer	PB	217/432	192/374	42/78	0.82	
Ihsan	2011	India	Asian	lung cancer	HB	82/94	51/133	55/63	0.22	
Bonaventure	2011	France	Caucasian	childhood acute leukemia	PB	255/263	197/190	41/32	0.77	
Sivonova	2012	Slovak	Caucasian	prostate cancer	PB	86/129	94/140	14/36	0.83	
Tumer	2012	Turkey	Asian	childhood ALL	PB	89/110	47/62	31/17	0.06	
Tilak	2011	India	Asian	lung cancer	PB	62/134	85/157	28/31	0.12	
Wang	2012	USA	Mixed	colorectal cancer	FB	167/188	108/141	28/29	0.72	
Balaji	2011	India	Asian	oral cancer	HB	71/49	61/64	25/19	0.8	
Cleary	2010	Canada	Caucasian	colorectal cancer	PB	561/625	502/549	100/118	0.87	
Hlavata	2010	Czech	Caucasian	colorectal cancer	HB	221/231	224/212	50/52	0.75	
Chauhan	2011	India	Asian	Adult AML	PB	50/77	48/85	22/40	0.07	
Ihsan	2010	India	Asian	esophageal cancer	PB	55/55	49/96	38/34	0.48	
Soucek	2010	Czech	Caucasian	HNC	PB	60/53	42/48	14/12	0.82	
Timofeeva	2010	Germany	Caucasian	lung cancer	PB	316/627	238/520	57/119	0.46	
MARIE-GENICA Consortium	2010	Germany	Caucasian	breast cancer	PB	1535/2671	1345/2322	267/490	0.65	
Sangrajrang	2009	Thailand	Asian	breast cancer	HB	143/125	286/247	128/115	0.74	
Ockenga	2009	Germany	Caucasian	pancreatic cancer	PB	167/304	164/311	36/64	0.22	
Jain	2008	India	Asian	esophageal cancer	PB	28/133	66/156	13/31	0.13	
Lacko	2008	Holland	Caucasian	HNC	PB	206/196	180/185	43/38	0.55	
Rosenberger	2008	Germany	Caucasian	lung cancer	PB	55/49	38/43	7/8	0.74	
Srivastava	2008	India	Asian	bladder cancer	unknown	26/78	57/64	23/18	0.38	
Skjelbred	2007	Norway	Caucasian	colorectal cancer	PB	52/132	41/134	9/33	0.91	
Mittal	2007	India	Asian	prostate cancer	unknown	26/62	67/60	37/18	0.56	
Justenhoven	2008	Germany	Caucasian	breast cancer	PB	296/295	246/269	63/45	0.12	
De Roos	2006	USA	Mixed	NHL	PB	528/469	471/383	104/69	0.45	
De Roos	2006	USA	Mixed	brain cancer	HB	313/268	213/216	69/43	0.95	
Clavel	2005	France	Mixed	childhood leukemia	HB	120/49	73/39	25/17	0.06	
van der Logt	2006	Holland	Caucasian	colorectal cancer	PB	185/194	141/165	39/32	0.71	
Landi	2005	Spain	Caucasian	colorectal cancer	HB	177/168	153/126	33/29	0.45	
Voho	2006	Finland	Caucasian	lung cancer	PB	133/1029	81/865	13/189	0.71	
Tranah	2005	USA	Caucasian	colorectal cancer	PB	219/439	190/371	34/81	0.84	
Robien	2005	USA	Mixed	colorectal cancer	PB	789/991	655/795	149/174	0.42	

Sarmanová	2004	Czech	Caucasian	breast cancer	HB	115/148	77/124	45/39	0.11
Gsur	2003	Austria	Caucasian	lung cancer	HB	147/224	114/218	16/54	0.93
Wenghoefer	2003	Germany	Caucasian	HNC	HB	142/136	112/128	26/25	0.51
Soucek	2002	Czech	Caucasian	lymphoma	PB	60/74	33/90	19/39	0.22
To-Figueras	2002	Spain	Caucasian	laryngeal cancer	PB	106/93	83/94	15/16	0.24
Spurdle	2001	Australia	Caucasian	ovarian cancer	PB	255/142	233/114	57/31	0.26
London	2000	USA	Caucasian	lung cancer	PB	85/237	82/184	15/37	0.88
London	2000	USA	African	lung cancer	PB	106/153	48/77	1/12	0.57
Benhamou	1998	France	Caucasian	lung cancer	HB	82/64	46/77	22/31	0.26

PB: population based; HB: hospital based; FB: family based

HWE: Hardy-Weinberg equilibrium (significant at the 0.05 level)

ALL: acute lymphoblastic leukemia; AML: acute myelocytic leukemia; HNC: head and neck cancer; NHL: Non Hodgkin lymphoma.